Pharm 2: Opioids

Front 1

Morphine

Back 1

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
Vaso dilator, metabolite more potent so adds to anaglesia

Front 2

Meperidine

Back 2

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
inc. oral potency, less resp. depression, DOC for OB

Front 3

Methadone

Back 3

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
very long 1/2, used in treatment of heroin addiction and opioid withdrawal

Front 4

Fentanyl

Back 4

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
80X more potent than morphine, muscular rigidity, TD patch

Front 5

Codeine

Back 5

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
analgesic effect via metabolism to morphine, w/ NSAIDs for cough

Front 6

Oxycodone

Back 6

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
=potent, inc. oral avail than morphine, combo w/ NSAIDs (oxycontin)

Front 7

Propoxyphene

Back 7

opioid receptor agonist
MOA: inhibition of adynylyl cyclase (dec cAMP, increase K conductance)
SE: respiratory depression, inc. intracranial pressure, N/V
1/2 potent as codeine, can have toxic build-up, cause irritation through IV

Front 8

Pentazocine (Talwin)

Back 8

Mixed opioid agonist/antagonist
MOA: Mu R antagonist, kappa R agonist
SE: less resp. depression, increased HR, BP, catecholamines

Front 9

Nalbuphine (Nubain)

Back 9

Mixed opioid agonist/antagonist
MOA: Mu R antagonist, kappa R agonist
SE: less resp. depression, increased HR, BP, catecholamines

unique in this class as doesn't exhibit significant cardiac effects
less likely to produce dysphoric effects

Front 10

Butorphanol (Stadol)

Back 10

Mixed opioid agonist/antagonist
MOA: Mu R antagonist, kappa R agonist
SE: less resp. depression, increased HR, BP, catecholamines
nasal spray

Front 11

Buprenorphine (Buprenex)

Back 11

Mixed opioid agonist/antagonist
MOA: Mu R antagonist, kappa R agonist
SE: less resp. depression, increased HR, BP, catecholamines
slow onset, long duration

Front 12

Naloxone (Narcan)

Back 12

Opioid Antagonists
MOA: blocks opioid R's (Mu best)
Gold standard, Tx or eval of opioid OD
used for neonatal resp. depression and mother takes opioids

Front 13

Naltrexone (Trexan, Revia)

Back 13

Opioid Antagonists
MOA: blocks opioid R's (Mu best)
higher oral efficacy than Naloxone
used as oral maintenance of opioid addicts, alcoholism

Front 14

Antitussive/Antidiarrheal opioids

Back 14

Codeine: depresses medulla cough center
Dextromethorphan: depresses medulla cough center
Diphenoxylate: depresses medulla cough center
Loperamide: no CNS effects